An Interventional, Phase III, Double-blind, Randomized, Controlled, Parallel-group, Multi-site, Clinical Trial Evaluating the Efficacy and Safety of Qutenza in Subjects With Post-surgical Neuropathic Pain
Latest Information Update: 20 Apr 2026
At a glance
- Drugs Capsaicin (Primary)
- Indications Neuropathic pain; Postoperative pain
- Focus Registrational; Therapeutic Use
- Acronyms RISE
- Sponsors Averitas Pharma
Most Recent Events
- 17 Apr 2026 Actual primary completion date changed from 7 Mar 2025 to 28 Aug 2025.
- 19 Feb 2025 Planned primary completion date changed from 30 Jan 2025 to 1 Mar 2025.
- 21 Nov 2024 Planned End Date changed from 1 May 2025 to 30 Aug 2025.